300 related articles for article (PubMed ID: 26285577)
21. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
22. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
[TBL] [Abstract][Full Text] [Related]
23. The discrepancy between central foveal thickness and best corrected visual acuity in cystoid macular edema secondary to central retinal vein occlusion after intravitreal lucentis® injection.
Hua R; Li C; Hu Y; Chen L
Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):310-3. PubMed ID: 25818575
[TBL] [Abstract][Full Text] [Related]
24. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA; Ip MS; Kulkarni AD
Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
[TBL] [Abstract][Full Text] [Related]
25. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
[TBL] [Abstract][Full Text] [Related]
26. Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion.
Kida T; Tsujikawa A; Muraoka Y; Harino S; Osaka R; Murakami T; Ooto S; Suzuma K; Morishita S; Fukumoto M; Suzuki H; Ikeda T
Ophthalmologica; 2016; 235(2):106-13. PubMed ID: 26800210
[TBL] [Abstract][Full Text] [Related]
27. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
29. Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion.
Shah GK; Sharma S; Fineman MS; Federman J; Brown MM; Brown GC
Am J Ophthalmol; 2000 Jan; 129(1):104-6. PubMed ID: 10653427
[TBL] [Abstract][Full Text] [Related]
30. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
Niederhauser N; Valmaggia C
Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
[TBL] [Abstract][Full Text] [Related]
31. Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series.
Nagasato D; Mitamura Y; Semba K; Akaiwa K; Nagasawa T; Yoshizumi Y; Tabuchi H; Kiuchi Y
BMC Ophthalmol; 2016 Apr; 16():36. PubMed ID: 27044276
[TBL] [Abstract][Full Text] [Related]
32. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
33. RELATIONSHIP BETWEEN CHOROIDAL FINDINGS AND GROWTH FACTORS, CYTOKINES, AND OTHER INFLAMMATORY MEDIATORS AFTER INTRAVITREAL RANIBIZUMAB INJECTION IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION.
Noma H; Yasuda K; Mimura T; Shimura M
Retina; 2022 Apr; 42(4):744-751. PubMed ID: 35350049
[TBL] [Abstract][Full Text] [Related]
34. [Six Months Outcome in Patients with Macular Edema Due to Retinal Vein Occlusion Treated with Ranibizumab].
Sakanishi Y; Ouchi A; Ito R; Ebihara N
Nippon Ganka Gakkai Zasshi; 2016 Jan; 120(1):28-34. PubMed ID: 26950966
[TBL] [Abstract][Full Text] [Related]
35. Retinal Vein Occlusion.
Sawada O; Ohji M
Dev Ophthalmol; 2016; 55():147-53. PubMed ID: 26501219
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analyses of optical coherence tomography in recurrent macular edema following intravitreal therapy in patients with retinal vein occlusion.
Holland SM; Dodwell DG; Krimmel DA; de Fiebre CM
BMC Ophthalmol; 2015 Sep; 15():117. PubMed ID: 26337708
[TBL] [Abstract][Full Text] [Related]
37. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
38. 3-Dimensional Visualization of Arteriovenous Crossing in a Branch Retinal Vein Occlusion.
Lo T; Yiu G
Ophthalmology; 2021 Mar; 128(3):363. PubMed ID: 33612162
[No Abstract] [Full Text] [Related]
39. Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.
Udaondo P; Díaz-Llopis M; García-Delpech S; Salom D; Romero FJ
Arch Ophthalmol; 2011 Mar; 129(3):283-7. PubMed ID: 21402982
[TBL] [Abstract][Full Text] [Related]
40. [Atypical macular holes].
Brüggemann A; Hoerauf H
Klin Monbl Augenheilkd; 2008 Apr; 225(4):281-5. PubMed ID: 18401794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
